BostonGene Corporation, a biomedical software company, today announced the appointment of Nathan Fowler, M.D., to the newly created position of Chief Medical Officer (CMO). Dr. Fowler joins BostonGene as it moves into the advanced stages of commercializing its personalized medicine solutions.
Dr. Fowler brings more than 20 years of patient care experience to BostonGene—most recently as a Professor of Medicine in the Department of Lymphoma/Myeloma at the University of Texas, MD Anderson Cancer Center. In addition to his role as CMO at BostonGene, Dr. Fowler will retain his affiliation with MD Anderson, continuing his involvement in the treatment of lymphoma patients while furthering his clinical research.
“We’re thrilled to welcome Dr. Fowler to BostonGene as a senior member of our management team,” said Andrew Feinberg, President and CEO at BostonGene. “His extensive experience researching and developing new therapies, combined with his commitment to discovering innovative solutions to treat patients, is invaluable to BostonGene as we continue to develop our solutions designed to treat the person, not the diagnosis.”
“I am honored to join BostonGene as its Chief Medical Officer,” said Nathan Fowler, M.D. “I have devoted my entire medical career to finding innovative solutions for cancer treatment, and I firmly believe BostonGene’s solution is fundamentally going to change how we treat cancer patients. I look forward to working with cancer centers from around the globe to drive change and improve the outcomes of all patients battling cancer.”
Dr. Fowler received his medical degree from the University of Texas, having completed his internship and residency there as well. He went on to complete a fellowship in hematology/oncology at Georgetown University Hospital in Washington D.C. At MD Anderson Cancer Center, Dr. Fowler focused on developing groundbreaking new therapies for cancer patients and led the clinical research program for nearly ten years. He is considered one of the world’s foremost experts in drug development for blood cancers, and his direct work led to the FDA approval of several novel agents in lymphoma. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination.
Dr. Fowler has published over 150 articles in peer-reviewed journals as well as numerous textbooks on innovative approaches to cancer therapy. Prior to his work in medicine, Dr. Fowler served in the U.S. Army as a nuclear, biological and chemical defense specialist. In addition, he serves as the President and Founder of Halo House Foundation, a non-profit organization providing housing to blood cancer patients receiving treatment.
About BostonGene Corporation
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision-making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient’s individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005211/en/